Published in Cancer Weekly, December 22nd, 1997
Results from the trial demonstrated an overall response rate to DEHOP of slightly better than 80 percent.
Enrollment in the study was limited to AIDS patients who were previously unresponsive to therapy with conventional antidiarrheal agents. The patients were hospitalized for three days prior to DEHOP therapy to establish baseline data and for three days post-therapy to determine drug efficacy on the refractory diarrhea. The drug was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.